Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-125382
Filing Date
2024-11-12
Accepted
2024-11-12 16:10:12
Documents
70
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q artv-20240930.htm   iXBRL 10-Q 2967694
2 EX-31.1 artv-ex31_1.htm EX-31.1 12331
3 EX-31.2 artv-ex31_2.htm EX-31.2 12351
4 EX-32.1 artv-ex32_1.htm EX-32.1 11862
  Complete submission text file 0000950170-24-125382.txt   10696715

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT artv-20240930.xsd EX-101.SCH 1421234
73 EXTRACTED XBRL INSTANCE DOCUMENT artv-20240930_htm.xml XML 1821557
Mailing Address 5505 MOREHOUSE DRIVE SAN DIEGO CA 92121
Business Address 5505 MOREHOUSE DRIVE SAN DIEGO CA 92121 (858) 267-4467
Artiva Biotherapeutics, Inc. (Filer) CIK: 0001817241 (see all company filings)

EIN.: 863614316 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-42179 | Film No.: 241448164
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)